Creo Medical Group PLC CEO Craig Gulliford talked with Proactive's Stephen Gunnion about the company’s 2024 performance and its strategy for 2025. He highlighted strong growth in Creo’s core technology platform, particularly in the US market, as well as the successful launch of the Speedboat UltraSlim device.
Gulliford also discussed the introduction of the SpydrBlade product, which is set for a full market release in 2025 alongside several other new product launches. He emphasised that Creo Medical is shifting from a development-stage company to a commercially profitable business, supported by both revenue growth and cost management.
In addition, he spoke about the completion of a €30 million deal with Micro-Tech, where Creo sold a 51% stake in Creo Medical Consumables Europe. This transaction enhances the company’s supply chain security and strengthens its direct sales channel in Europe. He noted that the valuation of the business has more than doubled since its acquisition four and a half years ago.
Gulliford confirmed that the company’s cash reserves have been bolstered by the deal, allowing further investment in expansion across Europe, the US, and emerging markets in South America and Asia. He also highlighted progress in Creo’s partnership with Intuitive on the Kamaptive platform, which has entered a commercialisation phase following the first robotically guided lung tumour ablation.
Looking ahead, investors can expect key milestones in 2025, including new product launches, further site expansions for Kamaptive, and continued revenue growth.
For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future updates.
#CreoMedical #MedicalTechnology #HealthcareInnovation #Endoscopy #SurgicalDevices #Kamaptive #CraigGulliford #ProactiveInvestors #StockMarket #Investing
